MACSF
VC Fund
La Défense, France
MACSF is a VC fund in La Défense focused on Health Care and Artificial Intelligence. Mutuelle d'Assurance du Corps de Santé Français (MACSF) is the provider of insurance to health professionals. MACSF protects and accompanies 950,000 members of all medical and paramedical specialties, offering professional and personal solutions in insurance, savings, financing, and pensions. Its products and services meet the real needs ofits members by accompanying them in the evolution of their profession and their projects.MACSF was founded in 1935.
- Total investments:
- 26
- Last investment:
- Lead investor:
- 12%
Last updated:
For AI agents: llms.txt
Industries MACSF invests in
Stages MACSF invests in
Countries MACSF invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
1 more contact available
Round size
- Seed
- $1.1M–$24M
- Series A
- $7.7M–$45M
- Series B
- $15M–$29M
Investment Focus
Industry
- Health Care 14 (54%)
- Artificial Intelligence 6 (23%)
- Medical Device 5 (19%)
- Medical 4 (15%)
- Software 3 (12%)
Stage
- Series A 7 (27%)
- Seed 5 (19%)
- Series B 3 (12%)
- Series C 3 (12%)
- Funding Round 3 (12%)
Country
- France 18 (69%)
- Spain 1 (4%)
- Ecuador 1 (4%)
- United States 1 (4%)
- The Netherlands 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Catherine Vinikoff
President of MACSF Insurance and LIBEA
|
President of MACSF Insurance and LIBEA | Total investments: 0 | Find email | |
Clement Canivet
Project Manager
|
Project Manager | Total investments: 0 | Find email | |
Philippe Eveilleau
President of MACSF SGAM, MACSF Pension, MACSF Retirement Savings, and MACSF Financement
|
President of MACSF SGAM, MACSF Pension, MACSF Retirement Savings, and MACSF Financement | Total investments: 0 | Find email | |
|
Stéphane Jaouen
IT Project Manager
|
IT Project Manager | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
DESTIA Group
|
DESTIA Group is a provider of personal services to different aged people. | Private Equity / Jun 24, 2026 | |
Enodia Therapeutics
|
Enodia Therapeutics is a biotech company that provides transforming treatments for cancer, inflammation, and viral infection diseases. | $24.2M / Seed / Jan 08, 2026 | |
RDS
|
RDS is a healthcare technology startup that specializes in remote patient monitoring solutions. The company's primary product, MultiSense®, is designed to help healthcare professionals continuously monitor patients' physiological parameters, whether they're in a hospital or at home. This innovative and multi-patented technology isaimed at improving patient pathways, which in turn enhances the quality of life and care efficiencies. The company's market is primarily hospitals (particularly surgical departments) and institutions that are looking for ways to improve patient care and reduce hospital stays. By facilitating early hospital discharge and continuous monitoring, RDS solution can contribute to significant healthcare savings. The MultiSense® solution is now CE marked (MDR) and is available for sale in several European countries. The company generates recurring revenues by providing the solution on a “fee for a service” business model to healthcare institutions and professionals. The product has been well-received in the market, earning multiple awards and the support of a vibrant community of clinicians. In addition to its primary product, RDS also provides services that help healthcare systems become more attractive and sustainable. This includes training and support for healthcare professionals to effectively use the MultiSense® technology. Keywords: Healthcare Technology, Remote Patient Monitoring, MultiSense®, Patient Pathways, Care Efficiencies, Hospital Discharge, Healthcare Savings, Clinicians, Physiological Parameters, Our main product, MultiSense®, is a comprehensive Remote Patient Monitoring Solution. MultiSense® offers healthcare professionals a high-precision, multi-parametric solution to continuously monitor patients’ physiological parameters in the hospital and beyond. MultiSense® combines a wearable patient monitor designed to capture high-accuracy physiological data with a cloud platform that helps transform these data into actionable clinical insights. MultiSense® is a patented medical device that has received multiple awards. MultiSense® has been validated by 6 completed clinical investigations.RDS relies on a talented and international team with deep subject-matter-expertise and a proven track record in the Healthcare and Medical Device sector. At RDS, we all share the same passion for bringing patient pathways to the next level. | $16.4M / Series A / Sep 29, 2025 | |
Pixmania
|
Pixmania is an e-commerce website that provides buying and selling of speakers, cameras, headphones, and mobile devices. | $12.1M / Seed / Jul 02, 2024 | |
Singulier
|
Singulier are a team of digital transformation entrepreneurs. Combining business consultancy, digital design thinking, marketing, technology and data to rapidly solve complex business problems for CEOs, their executives and investors. | $5.5M / Venture - Series Unknown / Dec 19, 2023 | |
|
RDS
|
RDS is a healthcare technology startup that specializes in remote patient monitoring solutions. The company's primary product, MultiSense®, is designed to help healthcare professionals continuously monitor patients' physiological parameters, whether they're in a hospital or at home. This innovative and multi-patented technology isaimed at improving patient pathways, which in turn enhances the quality of life and care efficiencies. The company's market is primarily hospitals (particularly surgical departments) and institutions that are looking for ways to improve patient care and reduce hospital stays. By facilitating early hospital discharge and continuous monitoring, RDS solution can contribute to significant healthcare savings. The MultiSense® solution is now CE marked (MDR) and is available for sale in several European countries. The company generates recurring revenues by providing the solution on a “fee for a service” business model to healthcare institutions and professionals. The product has been well-received in the market, earning multiple awards and the support of a vibrant community of clinicians. In addition to its primary product, RDS also provides services that help healthcare systems become more attractive and sustainable. This includes training and support for healthcare professionals to effectively use the MultiSense® technology. Keywords: Healthcare Technology, Remote Patient Monitoring, MultiSense®, Patient Pathways, Care Efficiencies, Hospital Discharge, Healthcare Savings, Clinicians, Physiological Parameters, Our main product, MultiSense®, is a comprehensive Remote Patient Monitoring Solution. MultiSense® offers healthcare professionals a high-precision, multi-parametric solution to continuously monitor patients’ physiological parameters in the hospital and beyond. MultiSense® combines a wearable patient monitor designed to capture high-accuracy physiological data with a cloud platform that helps transform these data into actionable clinical insights. MultiSense® is a patented medical device that has received multiple awards. MultiSense® has been validated by 6 completed clinical investigations.RDS relies on a talented and international team with deep subject-matter-expertise and a proven track record in the Healthcare and Medical Device sector. At RDS, we all share the same passion for bringing patient pathways to the next level. | $1.1M / Seed / Dec 01, 2023 | |
DocCity
|
DocCity LifeSciences creates and provides outstanding spaces to house cutting-edge healthcare businesses. DocCity provides clinicians with state-of-the-art, fully furnished health spaces with roomy, well-lit, and digitally equipped consultation rooms and reception areas. | $32.9M / Series A / Nov 27, 2023 | |
Gleamer
|
Gleamer develops an AI-powered software to enhance radiologists’ productivity. | $29.5M / Series B / Jun 28, 2023 | |
Braintale
|
Braintale develops and distributes accessible and effective diagnosis and prognosis tools for brain-injured patients.BrainTale’s products are based on medical needs understanding, fulfilling healthcare professionals and patients’ expectations, and is built upon more than 15 years of clinical development. The company was founded in 2018 and basedin Paris, France. | $4.9M / Jun 20, 2023 | |
i-Run
|
i-Run is a privately held French online retailer of running and fitness clothing company. | $97.9M / Secondary Market / Oct 06, 2022 | |
| See all 26 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does MACSF invest in?
MACSF invests primarily in Health Care, Artificial Intelligence and Medical Device startups, most often at Series A and Seed stage. Most of the 26 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is MACSF's check size?
MACSF typically joins rounds of $1.1M–$24M at Seed, $7.7M–$45M at Series A and $15M–$29M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds MACSF participates in.
How do I contact MACSF?
Public channels for MACSF include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at MACSF?
The team at MACSF includes Catherine Vinikoff (President of MACSF Insurance and LIBEA), Clement Canivet (Project Manager) and Philippe Eveilleau (President of MACSF SGAM, MACSF Pension, MACSF Retirement Savings, and MACSF Financement). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
